Antony Oliver Mary Chriselda, Graham Matthew, Manolopoulou Ioanna, Medley Graham F, Pellis Lorenzo, Pouwels Koen B, Thorpe Matthew, Hollingsworth T Deirdre
University of Cambridge, Department of Applied Mathematics and Theoretical Physics, Wilberforce Road, Cambridge, CB3 0BN, UK; University of Oxford, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Oxford, OX3 7LF, UK.
University of Oxford, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Oxford, OX3 7LF, UK.
J Theor Biol. 2025 Aug 21;611:112197. doi: 10.1016/j.jtbi.2025.112197. Epub 2025 Jun 20.
Cost-effectiveness analyses (CEA) typically involve comparing the effectiveness and costs of one or more interventions compared to the standard of care, in order to determine which intervention should be optimally implemented to maximise population health within the constraints of the healthcare budget. Traditionally, cost-effectiveness evaluations are expressed using incremental cost-effectiveness ratios (ICERs), which are compared with a fixed willingness-to-pay (WTP) threshold. Due to the inherent uncertainty in intervention costs and the overall burden of disease, particularly with regard to diseases in populations that are difficult to study, it becomes important to consider uncertainty quantification while estimating ICERs. To tackle the challenges of uncertainty quantification in CEA, we propose an alternative paradigm utilizing the Linear Wasserstein framework combined with Linear Discriminant Analysis (LDA) using a demonstrative example of lymphatic filariasis (LF). This approach uses geometric embeddings of the overall costs for treatment and surveillance, disability-adjusted life-years (DALYs) averted for morbidity by quantifying the burden of disease due to the years lived with disability, and probabilities of local elimination over a time-horizon of 20 years to evaluate the cost-effectiveness of lowering the stopping thresholds for post-surveillance determination of LF elimination as a public health problem. Our findings suggest that reducing the stopping threshold from <1 % to <0.5 % microfilaria (mf) prevalence for adults aged 20 years and above, under various treatment coverages and baseline prevalences, is cost-effective. When validated on 20 % of test data, for 65 % treatment coverage, a government expenditure of WTP ranging from $500 to $3000 per 1 % increase in local elimination probability justifies the switch to the lower threshold as cost-effective. Stochastic model simulations often lead to parameter and structural uncertainty in CEA. Uncertainty may impact the decisions taken, and this study underscores the necessity of better uncertainty quantification techniques within CEA for making informed decisions.
成本效益分析(CEA)通常涉及将一种或多种干预措施的有效性和成本与护理标准进行比较,以确定在医疗保健预算的限制范围内应最佳实施哪种干预措施,从而使人群健康最大化。传统上,成本效益评估使用增量成本效益比(ICER)来表示,并与固定的支付意愿(WTP)阈值进行比较。由于干预成本和疾病总体负担存在内在不确定性,特别是对于难以研究的人群中的疾病,在估计ICER时考虑不确定性量化变得很重要。为了应对CEA中不确定性量化的挑战,我们以淋巴丝虫病(LF)为例,提出了一种利用线性瓦瑟斯坦框架结合线性判别分析(LDA)的替代范式。这种方法通过量化因残疾生活年限导致的疾病负担,使用治疗和监测的总体成本、避免发病的残疾调整生命年(DALY)以及20年时间范围内局部消除的概率的几何嵌入,来评估降低LF作为公共卫生问题的监测后消除确定的停止阈值的成本效益。我们的研究结果表明,在各种治疗覆盖率和基线患病率下,将20岁及以上成年人的微丝蚴(mf)患病率停止阈值从<1%降低到<0.5%具有成本效益。在20%的测试数据上进行验证时,对于65%的治疗覆盖率,每1%的局部消除概率增加,政府支付意愿(WTP)范围从500美元到3000美元的支出证明转向较低阈值是具有成本效益的。随机模型模拟在CEA中常常导致参数和结构不确定性。不确定性可能会影响所做出的决策,本研究强调了在CEA中采用更好的不确定性量化技术以做出明智决策的必要性。